|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2002, Vol. 100, No. 4, pp. 1113-1122
PLENARY PAPER
Generation of polyclonal plasmablasts from peripheral blood B
cells: a normal counterpart of malignant plasmablasts
Karin Tarte,
John De
Vos,
Thomas Thykjaer,
Fenghuang Zhan,
Geneviève Fiol,
Valérie Costes,
Thierry Rème,
Eric Legouffe,
Jean-François Rossi,
John Shaughnessy Jr,
Torben F. Ørntoft, and
Bernard Klein
From the Unite de Thérapie Cellulaire, CHU
Montpellier; Laboratoire d'Anatomie Pathologique, CHU
Montpellier/Hôpital Gui de Chauliac; Service
d'Hémato-Oncologie Médicale, CHU Montpellier/Hôpital
Lapeyronie; INSERM U475, Montpellier, France; Aarhus University
Hospital, Skejby, Denmark; Donna and Donald Lambert Laboratory of
Myeloma Genetics, University of Arkansas for Medical Sciences, Little
Rock.
A new way to identify tumor-specific genes is to compare gene
expression profiles between malignant cells and their autologous normal
counterparts. In patients with multiple myeloma, a major plasma cell
disorder, normal plasma cells are not easily attainable in vivo. We
report here that in vitro differentiation of peripheral blood B
lymphocytes, purified from healthy donors and from patients with
multiple myeloma, makes it possible to obtain a homogeneous population
of normal plasmablastic cells. These cells were identified by their
morphology, phenotype, production of polyclonal immunoglobulins, and
expression of major transcription factors involved in B-cell differentiation. Oligonucleotide microarray analysis shows that these
polyclonal plasmablastic cells have a gene expression pattern close to
that of normal bone marrow-derived plasma cells. Detailed analysis of
genes statistically differentially expressed between normal and tumor
plasma cells allows the identification of myeloma-specific genes,
including oncogenes and genes coding for tumor antigens. These data
should help to disclose the molecular mechanisms of myeloma
pathogenesis and to define new therapeutic targets in this still fatal
malignancy. In addition, the comparison of gene expression between
plasmablastic cells and B cells provides a new and powerful tool to
identify genes specifically involved in normal plasma cell differentiation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. L. Carpenter, R. Mick, A. J. Rech, G. L. Beatty, T. A. Colligon, M. R. Rosenfeld, D. E. Kaplan, K.-M. Chang, S. M. Domchek, P. A. Kanetsky, et al.
Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
Clin. Cancer Res.,
July 1, 2009;
15(13):
4277 - 4287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Blood,
May 7, 2009;
113(19):
4614 - 4626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hose, T. Reme, T. Meissner, J. Moreaux, A. Seckinger, J. Lewis, V. Benes, A. Benner, M. Hundemer, T. Hielscher, et al.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Blood,
April 30, 2009;
113(18):
4331 - 4340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Piazza, M. Ruzzene, C. Gurrieri, B. Montini, L. Bonanni, G. Chioetto, G. Di Maira, F. Barbon, A. Cabrelle, R. Zambello, et al.
Multiple myeloma cell survival relies on high activity of protein kinase CK2
Blood,
September 1, 2006;
108(5):
1698 - 1707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Elsawa, A. J. Novak, D. M. Grote, S. C. Ziesmer, T. E. Witzig, R. A. Kyle, S. R. Dillon, B. Harder, J. A. Gross, and S. M. Ansell
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
Blood,
April 1, 2006;
107(7):
2882 - 2888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ettinger, G. P. Sims, A.-M. Fairhurst, R. Robbins, Y. S. da Silva, R. Spolski, W. J. Leonard, and P. E. Lipsky
IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells
J. Immunol.,
December 15, 2005;
175(12):
7867 - 7879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood,
August 1, 2005;
106(3):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. van Rhee, S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, et al.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Blood,
May 15, 2005;
105(10):
3939 - 3944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Avery, J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye
Increased Expression of CD27 on Activated Human Memory B Cells Correlates with Their Commitment to the Plasma Cell Lineage
J. Immunol.,
April 1, 2005;
174(7):
4034 - 4042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Bromage, I. M. Kaattari, P. Zwollo, and S. L. Kaattari
Plasmablast and Plasma Cell Production and Distribution in Trout Immune Tissues
J. Immunol.,
December 15, 2004;
173(12):
7317 - 7323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Houde, Y. Li, L. Song, K. Barton, Q. Zhang, J. Godwin, S. Nand, A. Toor, S. Alkan, N. V. Smadja, et al.
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
Blood,
December 1, 2004;
104(12):
3697 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, Y. Zhang, A. Mandal, J. Zhang, F. J. Giles, J. C. Herr, and S. H. Lim
The Spermatozoa Protein, SLLP1, Is a Novel Cancer-Testis Antigen in Hematologic Malignancies
Clin. Cancer Res.,
October 1, 2004;
10(19):
6544 - 6550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, and K. Tarte
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
Blood,
April 15, 2004;
103(8):
3148 - 3157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, J. R. Darce, B. K. Arendt, B. Harder, K. Henderson, W. Kindsvogel, J. A. Gross, P. R. Greipp, and D. F. Jelinek
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Blood,
January 15, 2004;
103(2):
689 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Davies, A. M. Dring, C. Li, A. C. Rawstron, M. A. Shammas, S. M. O'Connor, J. A.L. Fenton, T. Hideshima, D. Chauhan, I. T. Tai, et al.
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Blood,
December 15, 2003;
102(13):
4504 - 4511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr
Primer on Medical Genomics Part IX: Scientific and Clinical Applications of DNA Microarrays--Multiple Myeloma as a Disease Model
Mayo Clin. Proc.,
September 1, 2003;
78(9):
1098 - 1109.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Tarte, F. Zhan, J. De Vos, B. Klein, and J. Shaughnessy Jr
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation
Blood,
July 15, 2003;
102(2):
592 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al.
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
Blood,
May 1, 2003;
101(9):
3606 - 3614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology,
January 1, 2003;
2003(1):
248 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
